| EGFR基因突变及HER2/HER3蛋白表达水平与吉非替尼治疗晚期非小细胞肺癌疗效的关系 |
| |
| 引用本文： | 韩宇,徐建明,段海清,张杨,刘晓晴,张京生. EGFR基因突变及HER2/HER3蛋白表达水平与吉非替尼治疗晚期非小细胞肺癌疗效的关系[J]. 癌症, 2010, 29(1): 69-75 |
| |
| 作者姓名： | 韩宇 徐建明 段海清 张杨 刘晓晴 张京生 |
| |
| 作者单位： | 军事医学科学院307医院肿瘤中心;哈尔滨医科大学附属肿瘤医院;军事医学科学院生物工程研究所;大连医科大学第二附属医院肿瘤中心; |
| |
| 基金项目： | 全军“十一五”科技攻关项目(06G140);;黑龙江省青年科学基金(QC06068)~~ |
| |
| 摘 要： | 背景与目的:吉非替尼治疗非小细胞肺癌(NSCLC)的疗效不一,如何选择对吉非替尼敏感的患者,提高药物的疗效是临床中的难点。本研究探讨了中国人群中表皮生长因子受体(epidermal growth factor receptor,EGFR)的突变及HER2/HER3蛋白表达与吉非替尼治疗局部晚期或转移性NSCLC疗效的关系。方法:2002年5月至2005年2月,符合入组条件的106例患者每日口服250mg吉非替尼一次,直至疾病进展或出现不可耐受的毒副反应。收集吉非替尼治疗前的肿瘤组织。提取基因组DNA后,采用nest PCR技术扩增EGFR基因的18～24外显子,并从正反两个方向进行DNA测序和分析。同时采用免疫组化法检测84例肿瘤组织中的HER2/HER3蛋白的表达。结果:106例肿瘤标本中32例(30.2%)发生了突变。HER2高表达患者的有效率显著高于低表达的患者(36.8%vs.17.4%,P=0.044)。HER2/HER3的表达水平与疾病进展时间(TTP)及总生存期(OS)无关,但HER2/HER3高表达的患者生存期较低表达组略长(9.1个月vs.6.1个月,P=0.725;9.0个月vs.6.1个...
|
| 关 键 词： | 吉非替尼 EGFR HER2 HER3 基因突变 非小细胞肺癌 疗效 预后 |
Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib |
| |
| Yu Han,, Jian-Ming Xu, Hai-Qing Duan, Yang Zhang, Xiao-Qing Liu , Jing-Sheng Zhang. Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib[J]. Chinese journal of cancer, 2010, 29(1): 69-75 |
| |
| Authors: | Yu Han Jian-Ming Xu Hai-Qing Duan Yang Zhang Xiao-Qing Liu Jing-Sheng Zhang |
| |
| Affiliation: | Yu Han,1,2 Jian-Ming Xu,1 Hai-Qing Duan,3 Yang Zhang,4 Xiao-Qing Liu1 , Jing-Sheng Zhang31.Beijing 307 Hospital Cancer Center,Beijing,100071,P.R.China 2.Department of Oncology,The Affiliated Tumor Hospital of Harbin Medical University,Harbin,150040,Heilongjiang,P.R.China 3.Beijing Biotechnology Institute,P.R.China 4.The 2nd Affiliated Hospital Cancer Center,Dalian Medical University,Dalian,116027,Liaoning,P.R.China |
| |
| Abstract: | Background and Objective:The effect of gefitinib on advanced non-small cell lung cancer (NSCLC) was various.How to choose the sensitive patients and improve the effect was difficulty in clinic.This study was to assess the correlation of epidermal growth factor receptor (EGFR) mutations and HER2 /3 protein expression with the effect of gefitinib on Chinese patients with advanced NSCLC.Methods:From May 2002 to February 2005,a total of 106 Chinese NSCLC patients who had failed at least one chemotherapy regimen... |
| |
| Keywords: | gefitinib epidermal growth factor receptor HER2 HER3 mutation non-small cell lung cancer efficacy prognosis |
| 本文献已被 CNKI 等数据库收录！ |
|
